Inhibikase Therapeutics (IKT) Net Equity Issued and Repurchased (2020 - 2026)
Inhibikase Therapeutics (IKT) recorded Net Equity Issued and Repurchased of $2.9 million in Q1 2026, down 97.3% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
For FY2025, Inhibikase Therapeutics reported Net Equity Issued and Repurchased of $107.62 million, up 4.0% from FY2024.
- Annual Net Equity Issued and Repurchased has a five-year compound annual growth rate of 48.7% (FY2020 to FY2025).
- Across earlier years, Net Equity Issued and Repurchased came in at $103.48 million in FY2024, $8.54 million in FY2023, $44,142 in FY2022 (-99.9%) and $41.14 million in FY2021 (+178.2%).
- Quarterly Net Equity Issued and Repurchased has ranged from -$14,251 in Q3 2021 to $107.33 million in Q4 2025 over the past five years.
- On a year-over-year basis, Net Equity Issued and Repurchased rose in two of the last four quarters, with an average decline of 27.7%.
- Per Business Quant, the preceding three quarters came in at $107.33 million (Q4 2025), $250,932 (Q3 2025) and $31,621 (Q2 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | - |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | - |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 43.00 Mn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 6.00 Mn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 9.00 Mn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 47.70 Mn |
| 10 | Inhibikase Therapeutics | 359.62 Mn | -225.86 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 107.33 Mn |
| Sep 30, 2025 | 250,932.00 |
| Jun 30, 2025 | 31,621.00 |
| Dec 31, 2024 | 99.68 Mn |
| Sep 30, 2024 | 181,954.00 |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 397,607.00 |
| Dec 31, 2023 | 452.00 |
| Sep 30, 2023 | 70.00 |
| Jun 30, 2023 | 7.54 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Mar 31, 2022 | 44,142.00 |
| Sep 30, 2021 | -14,251.00 |
| Jun 30, 2021 | 41.15 Mn |
| Dec 31, 2020 | 14.78 Mn |
| Mar 31, 2020 | 4,870.00 |
API Access
Inhibikase Therapeutics Net Equity Issued and Repurchased API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-equity-issued-and-repurchased", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();